Boston, MA PolyMedix, Inc. (OTCBB: PYMX); Emerging World Pharma Inc. (PINKSHEETS: EWPI)
Stock Profiler welcomes investors to sign up at www.stockprofiler.us. to subscribe to our FREE Investor Tools, Newsletter, and Market Updates.
NOTE: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. To read the news in its entirety, go to the Leader in Market News, Stock Profiler.US, LLC (www.stockprofiler.us) click the Headline Tab, enter the ticker symbol and click the news link.
-
PolyMedix, Inc. closed at $1.10 Monday, trading 316,980 shares.
PolyMedix to Present at The Roth 22nd Annual Growth Stock Conference
RADNOR, Pa, March 08, 2010 PolyMedix, Inc. (OTCBB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, will be presenting at the Roth 22nd Annual Growth Stock Conference.
About PolyMedix, Inc.
PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of acute cardiovascular disorders and infectious diseases. PolyMedix's compounds are based on biomimetics: non-peptide small molecule drug candidates and polymers that mimic the activity of proteins. PMX-60056, PolyMedix's heptagonist compound, is being developed to reverse the activity of both heparin and low molecular weight heparins. PolyMedix plans to develop an antagonist drug that is safer and easier to use than currently approved therapy. PMX-30063, PolyMedix's antibiotic compound is a small molecule that mimics human host-defense proteins and has a completely different mechanism of action distinct from those of current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. PolyMedix's goal is to develop this compound as a rapidly acting antibiotic for serious systemic and local infections. Both PMX-60056 heptagonist and PMX-30063 antibiotic are currently undergoing clinical testing. PolyMedix also plans to continue the development of polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. For more information, please visit PolyMedix on its website at www.polymedix.com.
-
Emerging World Pharma Inc. closed at $0.00 Monday, trading 0 shares.
Emerging World Pharma Inc. Provides Initial Investment Into Private West African Generic Pharmaceutical Company
MANASSAS, VA, March 9, 2010 Emerging World Pharma Inc. (PINKSHEETS: EWPI), an investor in generic based pharmaceutical companies manufacturing within developing nations, has provided an initial investment into a private generic pharmaceutical company located in West Africa.
About Emerging World Pharma Inc.
Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.
The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups: church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.
-
About StockProfiler.US
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
-
Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com, http://www.fastmoneytalk.com, http://www.markettelegraph.com, http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.
Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
To view full disclaimers and terms of use, go to http://stockprofiler.us/?action=main.disclaimer.
-
Keywords: small cap stock, small cap news, small cap stock alerts, small cap stock updates, small cap stock news, small cap stock profile
((Comments on this story may be sent to info@m2.com))
